We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 2 for:    M15-736
Previous Study | Return to List | Next Study

Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson's Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04750226
Recruitment Status : Enrolling by invitation
First Posted : February 11, 2021
Last Update Posted : March 4, 2022
Sponsor:
Information provided by (Responsible Party):
AbbVie

Brief Summary:

Parkinson's disease (PD) is a neurological condition, which affects the brain. PD gets worse over time, but how quickly it progresses varies a lot from person to person. Some symptoms of PD are tremors, stiffness, and slowness of movement. This study will assess how safe and effective ABBV-951 is in adult participants with PD. Adverse events and change in disease activity is evaluated.

ABBV-951 is an investigational (unapproved) drug containing levodopa/carbidopa (LD/CD) given as an infusion under the skin for the treatment of Parkinson's Disease. Adult participants with advanced PD and who have completed M15-736 or M20-339 study will be enrolled. Approximately 130 participants will be enrolled in the study in approximately 60 sites in the United States and Australia.

Participants will receive continuous subcutaneous infusion (CSCI) (under the skin) of ABBV-951 for 96 weeks.

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the course of the study at a hospital or clinic. The effect of the treatment will be checked by medical and remote telephone assessments, blood tests, checking for side effects, and completing questionnaires.


Condition or disease Intervention/treatment Phase
Parkinson's Disease (PD) Drug: ABBV-951 Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 130 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-Label Extension of Studies M15-736 and M20-339 to Evaluate the Safety and Tolerability of 24-Hour Daily Exposure of ABBV-951 in Subjects With Advanced Parkinson's Disease
Actual Study Start Date : February 18, 2021
Estimated Primary Completion Date : October 12, 2024
Estimated Study Completion Date : October 12, 2024

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: ABBV-951
Participants will receive ABBV-951 by continuous subcutaneous infusion (CSCI) for 96 weeks.
Drug: ABBV-951
Solution for continuous subcutaneous infusion (CSCI).
Other Names:
  • Carbidopa
  • Levodopa




Primary Outcome Measures :
  1. Percentage of Participants with Adverse Event (AEs) [ Time Frame: Up to Week 96 ]
    An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. An SAE is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the subject and may require medical or surgical intervention to prevent any of the outcomes listed above.

  2. Percentage of Participants with AEs of Special Interest (AESIs) [ Time Frame: Up to Week 96 ]
    AESIs are defined as AEs from "special situations," such as accidental or intentional overdose, medication error, occupational or accidental exposure, off-label use, drug abuse, drug misuse, or drug withdrawal, all which must be reported whether associated with an AE or not.

  3. Percentage Of Participants With Numeric Grade Equal To Or Higher Than 5 On The Infusion Site Evaluation Scale [ Time Frame: Up To Week 96 ]
    The Infusion Site Evaluation Scale will be used to assess infusion sites. Infusion Site Evaluation Scale is an eight-point numeric scale used to assess irritation at the infusion site area (0 being "no evidence of irritation" and 7 being "strong reaction spreading beyond the test site").

  4. Percentage Of Participants With Letter Grade Equal To Or Higher Than D On The Infusion Site Evaluation Scale [ Time Frame: Up To Week 96 ]
    The Infusion Site Evaluation Scale will be used to assess infusion sites. Infusion Site Evaluation Scale is an A to G letter grade scale, used to assess irritation at the infusion site area (A being "no finding" to G being "Small petechial erosions and/or scabs").

  5. Change From Baseline in Suicidality as assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS) [ Time Frame: Up To Week 96 ]
    C-SSRS is a systematically administered instrument designed to assess suicidal behavior and ideation, track and assess all suicidal events, and assess the lethality of attempts. Any participant who has suicidal behavior or suicidal ideation with plan since the last C-SSRS completed, will be evaluated immediately by the investigator.

  6. Change From Baseline in Impulsive-Compulsive Disorders and related behaviors as assessed in Parkinson's Disease- Rating Scale (QUIP-RS) [ Time Frame: Up To Week 96 ]
    The QUIP-RS is a brief, self-completed or rater-administered rating scale to assess the severity of symptoms of impulse control disorders (ICDs) and related behaviors reported to occur in PD. The QUIP-RS uses a 5-point Likert scale that requires individuals to rate the severity of each symptom based on its frequency.

  7. Change From Baseline in Cognitive Impairment as Assessed by the Mini-Mental State Examination (MMSE) [ Time Frame: Up To Week 96 ]
    Cognitive impairment is assessed by the Mini-Mental State Examination (MMSE). MMSE is a brief 30-point questionnaire, administered by a trained rater, that provides a quantitative measure of cognitive status in adults and is used widely to screen for cognitive impairment and to estimate the severity of cognitive impairment at a given point in time, to follow the course of changes in a patient over time, and to document response to treatment.

  8. Number of Participants with Abnormal Change in Clinical Laboratory Test Results Like Hematology will be Assessed. [ Time Frame: Up to Week 96 ]
    Number of participants with abnormal change in clinical laboratory test results like hematology will be assessed..

  9. Number of Participants with Abnormal ChangeFrom Baseline in Vital Sign Measurements like Systolic and Diastolic Blood Pressure will be Assessed [ Time Frame: Up to Week 96 ]
    Number of participants with abnormal change from baseline in vital sign measurements like systolic and diastolic blood pressure will be assessed.

  10. Change From Baseline in Electrocardiograms (ECGs) [ Time Frame: Up to Week 96 ]
    12-lead resting ECGs will be recorded. Parameters include RR interval, PR interval, QT interval, and QRS duration.


Secondary Outcome Measures :
  1. Change From Baseline in Average Normalized "On" Time as Assessed by the Parkinson's Disease (PD) Diary [ Time Frame: Up To Week 96 ]
    Change in "On" time without dyskinesia or with non-troublesome dyskinesia as assessed by the PD diary.

  2. Change From Baseline in Average Daily Normalized "Off" Time as Assessed by the PD Diary [ Time Frame: Up To Week 96 ]
    Change in average daily normalized "Off" Time (Hours) is assessed based on PD Diary.

  3. Change From Baseline in PD Symptoms as Assessed by the MDS-UPDRS Tool Part I [ Time Frame: Up To Week 96 ]
    The MDS-UPDRS is an investigator-used rating tool to follow the longitudinal course of Parkinson's Disease (PD) with scores ranging from 0 to 236 with 236 representing the worst disability, and 0 representing no disability.

  4. Change From Baseline in Motor Experiences of Daily Living [ Time Frame: Up To Week 96 ]
    Motor experiences of daily living is assessed by the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part II. The MDS-UPDRS is an investigator-used rating tool to follow the longitudinal course of Parkinson's Disease (PD) with scores ranging from 0 to 236 with 236 representing the worst disability, and 0 representing no disability.

  5. Change From Baseline in PD Symptoms as Assessed by the MDS-UPDRS Tool Part III [ Time Frame: Up To Week 96 ]
    The MDS-UPDRS is an investigator-used rating tool to follow the longitudinal course of Parkinson's Disease (PD) with scores ranging from 0 to 236 with 236 representing the worst disability, and 0 representing no disability.

  6. Change From Baseline in PD Symptoms as Assessed by the MDS-UPDRS Tool Part IV [ Time Frame: Up To Week 96 ]
    The MDS-UPDRS is an investigator-used rating tool to follow the longitudinal course of Parkinson's Disease (PD) with scores ranging from 0 to 236 with 236 representing the worst disability, and 0 representing no disability.

  7. Change From Baseline in PD Symptoms as Assessed by the MDS-UPDRS Tool Parts I-III [ Time Frame: Up To Week 96 ]
    The MDS-UPDRS is an investigator-used rating tool to follow the longitudinal course of Parkinson's Disease (PD) with scores ranging from 0 to 236 with 236 representing the worst disability, and 0 representing no disability.

  8. Change From Baseline in Sleep Symptoms [ Time Frame: Up To Week 96 ]
    Sleep symptoms are assessed by the Parkinson's Disease Sleep Scale-2 (PDSS-2). The PDSS-2 consists of 15 questions that evaluate motor and non-motor symptoms at night and upon wakening, as well as disturbed sleep.

  9. Change From Baseline in Quality Of Life as Assessed by the PD Questionnaire-39 item (PDQ-39) [ Time Frame: Up To Week 96 ]
    Quality of life is assessed by the PD Questionnaire-39 item (PDQ-39). PDQ-39 is a disease-specific instrument designed to measure aspects of health that are relevant to participants with PD, and which may not be included in general health status questionnaires. Each item is scored on a 5-point scale.

  10. Change From Baseline in Health-related Quality of Life as Assessed by EQ-5D-5L [ Time Frame: Up To Week 96 ]
    Health-related quality of life is assessed by EQ-5D-5L. EQ-5D-5L is a standardized instrument that consists of 2 parts: the EQ-5D descriptive system and the EQ visual analogue-scale (EQ-VAS).

  11. Percentage Of Participants With Early Morning "Off" Assessed by the PD Diary as Percentage of Participants with early morning "Off" Upon Waking Up [ Time Frame: Up To Week 96 ]
    Early morning "Off" status is assessed by the PD Diary as percentage of participants with early morning "Off" upon waking up.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   30 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

- Completion of the parent study, Study M15-736 or Study M20-339.

Exclusion Criteria:

- Participant considered by the investigator to be an unsuitable candidate to receive ABBV-951 for any reason.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04750226


Locations
Show Show 51 study locations
Sponsors and Collaborators
AbbVie
Investigators
Layout table for investigator information
Study Director: ABBVIE INC. AbbVie
Layout table for additonal information
Responsible Party: AbbVie
ClinicalTrials.gov Identifier: NCT04750226    
Other Study ID Numbers: M20-098
2019-004204-35 ( EudraCT Number )
First Posted: February 11, 2021    Key Record Dates
Last Update Posted: March 4, 2022
Last Verified: February 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Clinical Study Report (CSR)
Time Frame: Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.
Access Criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.
URL: https://www.abbvie.com/our-science/clinical-trials/clinical-trials-data-and-information-sharing/data-and-information-sharing-with-qualified-researchers.html

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
Keywords provided by AbbVie:
Parkinson's Disease
PD
ABBV-951
Levodopa/Carbidopa (LD/CD)
Levodopa Phosphate/Carbidopa Phosphate (LDP/CDP)
Additional relevant MeSH terms:
Layout table for MeSH terms
Parkinson Disease
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Synucleinopathies
Neurodegenerative Diseases
Levodopa
Carbidopa
Antiparkinson Agents
Anti-Dyskinesia Agents
Dopamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Aromatic Amino Acid Decarboxylase Inhibitors
Enzyme Inhibitors